Rivaroxaban is an oral direct Factor Xa inhibitor that provides predictable, dose-dependent anticoagulation without the need for routine coagulation monitoring or dietary restrictions. It offers a rapid onset of action and convenient once or twice-daily dosing. Indicated for stroke prevention in non-valvular atrial fibrillation, treatment and secondary prevention of deep vein thrombosis and pulmonary embolism, VTE prophylaxis following elective hip or knee replacement surgery, and prevention of atherothrombotic events in coronary or peripheral artery disease.